SANA

Sana Biotechnology, Inc.

Fundamental data last updated:November 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

 


Analyze SANA on TradingView

VALUATION

P/E

-3.58

Market Cap ($M USD)

$871.05M

Forward P/E

-5.03

PEG

-0.17

PRICE TO SALES

0.00

PRICE TO BOOK

7.27

EV / EBITDA

-4.79

5-Year Average P/E

Free Cash Flow Yield

-15.34%

DCF Value

$-0.03

Graham Number

N/A

Price to FCF

-6.52

EV to FCF

-6.45

Earnings Yield

-27.93%

FCF Yield

-15.34%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.87

Next Year EPS Growth Estimate

-$0.62

Next Year Revenue Growth Estimate

$26.25M

Return on Equity (ROE)

-161.87%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.49

Piotroski F-Score

1

Altman Z-Score

-6.67

Return on Invested Capital (ROIC)

-82.68%

Current Ratio

1.29

Quick Ratio

1.29

Net Debt to EBITDA

0.05

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-0.48

REVENUE PER SHARE

$0.00

Analyze SANA on TradingView

Gainseekers Quantitative Analysis

Summary

SANA’s valuation paints a grim picture. The market has priced it significantly above its DCF value, suggesting a disconnect between current expectations and intrinsic worth. With a Forward P/E of -5.55 and an Altman Z-score of -5.44, the company is in precarious financial health, signaling potential distress. The negative earnings yield further underscores the lack of profitability, raising red flags for growth and safety. This is a stock that demands caution, as its financial metrics suggest more risk than reward.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, SANA is positioned to leverage advancements in AI for drug discovery and development. The industry's inherent focus on innovation aligns well with technological shifts, potentially enhancing research efficiency. However, execution risk remains high, as success hinges on translating tech advancements into tangible breakthroughs.

The Bull Case

For the optimistic investor, SANA's potential lies in its staggering projected sales growth of 2,625,000,000%. Despite a low Piotroski F-Score of 1, which indicates weak financial health, the company's low debt-to-equity ratio of 0.49 suggests manageable leverage. The absence of operating margins and a negative ROIC of -74.02% highlight inefficiencies, yet the market's "Buy" consensus rating hints at institutional confidence in future prospects.

The Bear Case

The bear case for SANA is compelling. A Price/Book ratio of 5.52 indicates overvaluation, especially when juxtaposed with zero revenue per share and a negative FCF yield of -15.45%. The Altman Z-score of -5.44 signals severe financial distress, while the stock's proximity to its 52-week low suggests technical weakness. These metrics paint a picture of a company struggling to justify its market cap.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$8.67

Institutional Ownership %

1-Year Beta

2.18

Insider Buying % (6 Mo)

Distance to 52-Week High

109.27%

Distance to 52-Week Low

32.91%

EARNINGS SURPRISE %

6.67%

50-DAY SMA

$3.24

200-DAY SMA

$3.86

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.